en · de · es
analytical-notes.peptides5388.com › Data › Background And Receptor Mechanism — Questions and Answers

Background And Receptor Mechanism — Questions and Answers

By Editorial Desk · published 2026-04-19 · last reviewed 2026-05-14 · Data

nuclear receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-05-14. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Receptor Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

Background and Pharmacological Mechanism

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small moleculeStudied as a REV-ERB agonist
Molecular formulaC20H24ClN3O4SReported for the neutral compound
AppearanceOff-white to pale yellow solidTypical research-grade material
SolubilitySparingly soluble in waterSoluble in solvents such as DMSO
Common synonymsSR9009; StenabolicStenabolic is an informal alias

SR9009 Identity and Mechanism

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

Related pages on this site

Analytical and Handling Considerations

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Further detail

v Apotex Corp) for patent infringement by producing quantities of the newer paroxetine polymorph in their generic pills, asking for their products to be blocked from entering the market. GSK claimed that the anhydrate "inevitably" converts to hemihydrate due to the presence of seeds. Apotex rejected the seeding theory as "junk science" and "alchemy". Both the District Court and the Federal Circuit Court accepted the seeding theory of GSK, but nevertheless both judged in favor of Apotex. The District Court judged that Apotex was not responsible for unintentional presence of seeding in facility. The Federal Circuit Court invalidated the newer patent concerning the hemihydrates, on the argument of prior public use from the clinical trials. Later research showed that the "anhydrate" was in fact a non-stoichiometric hydrate that rapidly dehydrates and rehydrates. The hemihydrate form is more stable due to a higher number of hydrogen bonds.

=== General characteristics of the active substance === Salmon calcitonin is rapidly absorbed and eliminated. Peak plasma concentrations are attained within the first hour of administration. Animal studies have shown that calcitonin is primarily metabolised via proteolysis in the kidney following parenteral administration. The metabolites lack the specific biological activity of calcitonin. Bioavailability following subcutaneous and intramuscular injection in humans is high and similar for the two routes of administration (71% and 66%, respectively). Calcitonin has short absorption and elimination half-lives of 10–15 minutes and 50–80 minutes, respectively. Salmon calcitonin is primarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule. Therefore, the metabolic clearance is much lower in patients with end-stage kidney failure than in healthy subjects. However, the clinical relevance of this finding is not known. Plasma protein binding is 30% to 40%.

== Overdose == An overdose of pregabalin usually consists of severe drowsiness, severe ataxia, blurred vision, slurred speech, uncontrollable jerking motions (myoclonus), and anxiety. In one case study, macular detachment was reported with overdose Despite these symptoms an overdose is not usually fatal unless mixed with another CNS depressant. Several people with kidney failure developed myoclonus while receiving pregabalin, apparently as a result of the gradual accumulation of the drug. Acute overdosage may be manifested by drowsiness, tachycardia, and hypertonia. Plasma, serum, or blood concentrations of pregabalin may be measured to monitor therapy or to confirm a diagnosis of poisoning in hospitalized people.

Sources: en.wikipedia.org

Background from the literature

=== Reproduction studies === Patulin decreased sperm count and altered sperm morphology in the rat. Also, it resulted in abortion of F1 litters in rats and mice after i.p. injection. Embryotoxicity and teratogenicity were also reported in chick eggs.

=== Collecting === A self-professed bibliophile, Szathmary began collecting books shortly after arriving in America, which culminated in a collection of 45,000 books and culinary materials. Szathmary was raised in a bookish family that had a standing account with a book dealer since the 1790s. Szathmary's collection comprises culinary books and handwritten manuscripts, a menu collection, Hungarian collections, and letters from Hungarian composer Franz Liszt. Szathmary stored his collection in the upstairs rooms of The Bakery restaurant building in thirty-one rooms in seventeen apartments. This immense collection has been divided and donated to various universities and institutions: The Szathmary Culinary Collection at the University of Iowa, the Szathmary Hungarica Collection at the University of Chicago, a collection of personal papers at DePaul University in Chicago, a collection of letters to and from Franz Liszt donated to the Liszt collection at Boston University and a 400,000-item culinary arts collection including menus which became the foundation for the Culinary Archives and Museum at Johnson & Wales University in Providence, Rhode Island.

For most people, irritation from formaldehyde is temporary and reversible, although formaldehyde can cause allergies and is part of the standard patch test series. In 2005–06, it was the seventh-most-prevalent allergen in patch tests (9.0%). People with formaldehyde allergy are advised to avoid formaldehyde releasers as well (e.g., Quaternium-15, imidazolidinyl urea, and diazolidinyl urea). People who suffer allergic reactions to formaldehyde tend to display lesions on the skin in the areas that have had direct contact with the substance, such as the neck or thighs (often due to formaldehyde released from permanent-press finished clothing) or dermatitis on the face (typically from cosmetics). Formaldehyde has been banned in cosmetics in both Sweden and Japan.

Sources: en.wikipedia.org

Reference notes

On 16 November, Hezbollah conducted eight anti-tank missiles targeting Israeli forces and military infrastructure. In the afternoon, Hezbollah attacked numerous towns near the border and targeted military gatherings in Shtula and Hadab Yaron. The IDF responded heavily in southern Lebanon and Israeli warplanes raided Hezbollah targets. Hezbollah announced that two of its members were killed. Four days later, the IDF base of Biranit suffered heavy damage from a Hezbollah barrage using Burkan rockets. IDF fighter jets struck numerous Hezbollah military targets, and soldiers struck a militant cell near Metula. The historically significant St. George church was heavily damaged in Yaroun after it was shelled by the IDF. The house of Amal Movement MP Kabalan Kabalan was also hit with rocket fire. Hezbollah claimed an attack on the IDF's 91st Division barracks at Baranit. On 21 November, an IDF airstrike in Kafr Kila killed an elderly woman and injured her granddaughter. Another team of journalists were targeted in an IDF strike near Tayr Harfa which killed three people, including two Al Mayadeen journalists, a reporter and a photojournalist, and a guide. On the same day, four members of the Al-Qassam Brigades were killed after an IDF strike on a car near Chaaitiyeh. A Hezbollah member was also killed in a separate attack in Khiam. Hezbollah told Al Jazeera that it would "respect" the temporary ceasefire deal between Israel and Hamas reached on 24 November 2023.

==== Ion exchange ==== It is common for medium active wastes in the nuclear industry to be treated with ion exchange or other means to concentrate the radioactivity into a small volume. The much less radioactive bulk (after treatment) is often then discharged. For instance, it is possible to use a ferric hydroxide floc to remove radioactive metals from aqueous mixtures. After the radioisotopes are absorbed onto the ferric hydroxide, the resulting sludge can be placed in a metal drum before being mixed with cement to form solid waste. In order to get better long-term performance (mechanical stability) from such forms, they may be made from a mixture of fly ash, or blast furnace slag, and portland cement, instead of normal concrete (made with portland cement, gravel and sand).

=== General insulins === Insulins that are used mostly in humans are sometimes also used in animals such as cats and dogs. These include Lantus (insulin glargine), Novolin (NPH insulin), Humulin (NPH insulin), and Levemir (Detemir). It is of note that one of the listed insulins other than lente and PZI are FDA-approved for use in animals.

The number of growers expanded from 7,600 to at least 40,000 over the same period. Besides growers, the coca networks employed numerous Bolivians, including carriers (zepeadores), manufacturers of coca paste and cocaine, security personnel, and a large variety of other positions. The unparalleled revenues made the risk worthwhile for many. Government efforts to eradicate the expansion of coca cultivation in Bolivia began in 1983, when Bolivia committed itself to a five-year program to reduce coca production and created the Coca Eradication Directorate (Dirección de la Reconversión de la Coca—Direco) under the Ministry of Agriculture, Campesino Affairs, and Livestock Affairs. Bolivia's National Directorate for the Control of Dangerous Substances (Dirección Nacional para el Control de Substancias Peligrosas—DNCSP) was able to eradicate several thousand hectares of coca. These efforts put only a small dent in the coca industry and were highly controversial among thousands of peasants. Under the joint agreement signed by the United States and Bolivia in 1987, which created the DNCSP, Bolivia allocated US$72.2 million for the 1988 to 1991 period to eradication programs, including a wide-ranging rural development program for the Chapare region. The program was aided by an 88 percent drop in the local price of coca caused by the fall in cocaine prices in the United States. The economics of eradication were particularly frustrating. As more coca was destroyed, the local price increased, making it more attractive to other growers.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Is SR9009 a SARM?

No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.

What human data exist for SR9009?

Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.

What is SR9009?

It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.

Network